Edition:
India

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,371JPY
11:30am IST
Change (% chg)

¥-14 (-0.32%)
Prev Close
¥4,385
Open
¥4,400
Day's High
¥4,400
Day's Low
¥4,361
Volume
3,207,600
Avg. Vol
5,184,921
52-wk High
¥4,822
52-wk Low
¥3,401

Latest Key Developments (Source: Significant Developments)

Evotec, Takeda Enter Collaboration Across Multiple Therapeutic Fields
Tuesday, 24 Sep 2019 

Sept 24 (Reuters) - Evotec Se ::DGAP-NEWS: EVOTEC AND TAKEDA ENTER COLLABORATION AGREEMENT TO DISCOVER CLINICAL CANDIDATES ACROSS MULTIPLE THERAPEUTIC AREAS.MULTI-YEAR SMALL MOLECULE DRUG DISCOVERY COLLABORATION WITH A RISK SHARING, SUCCESS DRIVEN MODEL.EVOTEC LEADS INTEGRATED PROGRAMMES WITH TAKEDA HAVING OPTIONS AT LEAD SERIES AND CANDIDATE.EVOTEC RECEIVES UNDISCLOSED UPFRONT PAYMENT AND CAN EARN FUTURE MILESTONE AND ROYALTY PAYMENTS.PARTIES AIM TO ESTABLISH AT LEAST FIVE DRUG DISCOVERY PROGRAMMES WITH GOAL OF EVOTEC DELIVERING CLINICAL CANDIDATES FOR TAKEDA TO PURSUE INTO CLINICAL DEVELOPMENT.EVOTEC IS ELIGIBLE TO RECEIVE PRE-CLINICAL, CLINICAL, AND COMMERCIAL MILESTONES THAT CAN TOTAL IN EXCESS OF $ 170 M PER PROGRAMME AS WELL AS TIERED ROYALTIES ON FUTURE SALES.  Full Article

Kamada Reports Discussions With Takeda Regarding A Potential Extension Of The Period For The Transition Of Glassia Manufacturing To Takeda
Thursday, 8 Aug 2019 

Aug 8 (Reuters) - Kamada Ltd ::KAMADA REPORTS DISCUSSIONS WITH TAKEDA REGARDING A POTENTIAL EXTENSION OF THE PERIOD FOR THE TRANSITION OF GLASSIA MANUFACTURING TO TAKEDA.KAMADA LTD - GLASSIA SUPPLY AGREEMENT WITH TAKEDA CURRENTLY EXTENDS THROUGH END OF 2020.KAMADA LTD - TRANSITION OF GLASSIA MANUFACTURING TO TAKEDA AFTER 2020 WILL RESULT IN A SIGNIFICANT REDUCTION OF KAMADA'S REVENUES.KAMADA LTD - BASED ON CURRENT TERMS OF SUPPLY AGREEMENT, KAMADA WOULD BE ENTITLED TO FUTURE ROYALTY PAYMENTS UNTIL 2040..  Full Article

Takeda Says Investigational Subcutaneous Formulation Of Vedolizumab Meets Primary Endpoint In Achieving Clinical Remission At Week 52 In Patients With Moderately To Severely Active Crohn's Disea
Monday, 22 Jul 2019 

July 22 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::INVESTIGATIONAL SUBCUTANEOUS FORMULATION OF VEDOLIZUMAB MEETS PRIMARY ENDPOINT IN ACHIEVING CLINICAL REMISSION AT WEEK 52 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE.VEDOLIZUMAB SUBCUTANEOUS CURRENTLY UNDER REVIEW FOR APPROVAL FOR ULCERATIVE COLITIS WITH EUROPEAN MEDICINES AGENCY, U.S. FDA.  Full Article

Molecular Templates Announces FDA Acceptance Of IND Application For TAK-169, An Engineered Toxin Body Targeting CD38
Monday, 17 Jun 2019 

June 17 (Reuters) - Molecular Templates Inc ::MOLECULAR TEMPLATES ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR TAK-169, AN ENGINEERED TOXIN BODY TARGETING CD38.MOLECULAR TEMPLATES INC - CO, TAKEDA CO-DEVELOPING TAK-169.  Full Article

Skyhawk Therapeutics Announces Agreement With Takeda To Develop Novel Small Molecule Rna Splicing Modifiers
Monday, 6 May 2019 

May 6 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::SKYHAWK THERAPEUTICS ANNOUNCES AGREEMENT WITH TAKEDA TO DEVELOP NOVEL SMALL MOLECULE RNA SPLICING MODIFIERS FOR NEURODEGENERATIVE DISEASES.  Full Article

Exelixis' Partner Takeda Announces Filing Of NDA In Japan For Cabometyx For Advanced Renal Cell Carcinoma
Thursday, 25 Apr 2019 

April 25 (Reuters) - Exelixis Inc ::EXELIXIS’ PARTNER TAKEDA ANNOUNCES FILING OF NEW DRUG APPLICATION IN JAPAN FOR CABOMETYX® (CABOZANTINIB) FOR ADVANCED RENAL CELL CARCINOMA.EXELIXIS INC - REGULATORY SUBMISSION TRIGGERS $10 MILLION MILESTONE PAYMENT TO EXELIXIS UNDER COLLABORATION AND LICENSE AGREEMENT WITH TAKEDA.EXELIXIS INC - EXELIXIS WILL RECEIVE A $10 MILLION MILESTONE PAYMENT FROM TAKEDA, ANTICIPATED TO BE RECEIVED IN Q2 OF 2019.EXELIXIS INC - SUBMISSION BASED ON METEOR AND CABOSUN TRIALS AS WELL AS TAKEDA BRIDGING STUDY.  Full Article

LegoChem Biosciences, Takeda Enter into Multi-Target Research Collaboration and License Agreement
Friday, 22 Mar 2019 

March 22 (Reuters) - LegoChem Biosciences Inc <141080.KQ>::LEGOCHEM BIOSCIENCES, TAKEDA ENTER INTO MULTI-TARGET RESEARCH AND LICENSE AGREEMENT FOR DEVELOPMENT OF ANTIBODY-DRUG CONJUGATES IN IMMUNO-ONCOLOGY.TAKEDA OBTAINS RIGHTS TO LCB'S ADC PLATFORM FOR MULTIPLE TARGETS.LCB WILL RECEIVE $7.25 MILLION IN UPFRONT AND NEAR-TERM MILESTONE PAYMENTS..LCB ELIGIBLE TO RECEIVE DEVELOPMENT, REGULATORY, COMMERCIAL MILESTONE PAYMENTS OF UP TO $404 MILLION.LCB ELIGIBLE TO RECEIVE ROYALTIES ON SALES OF ANY RESULTING ADC PRODUCTS.  Full Article

Takeda And Hemoshear Therapeutics Extend Exclusive Drug Discovery Partnership In Liver Diseases
Wednesday, 20 Mar 2019 

March 20 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA AND HEMOSHEAR THERAPEUTICS EXTEND EXCLUSIVE DRUG DISCOVERY PARTNERSHIP IN LIVER DISEASES.HEMOSHEAR THERAPEUTICS- HEMOSHEAR WAS ELIGIBLE TO RECEIVE MILESTONE PAYMENTS OF POTENTIALLY $470 MILLION AND ROYALTIES.HEMOSHEAR THERAPEUTICS- FURTHER ADDITIONAL FINANCIAL TERMS RELATED TO EXTENSION OF PARTNERSHIP WERE NOT DISCLOSED.  Full Article

Takeda Receives U.S. FDA Approval To Manufacture Flexbumin At New Plasma Manufacturing Facility
Monday, 18 Mar 2019 

March 18 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA RECEIVES U.S. FDA APPROVAL TO MANUFACTURE FLEXBUMIN® AT NEW PLASMA MANUFACTURING FACILITY NEAR COVINGTON, GEORGIA.TAKEDA PHARMACEUTICAL - FDA APPROVED SECOND SUBMISSION FOR ITS NEW PLASMA MANUFACTURING FACILITY FOR PRODUCTION OF FLEXBUMIN 25% USP, 25% SOLUTION.  Full Article

Infinity Pharmaceuticals Announces Royalty Monetization Of COPIKTRA For $30 Mln Gross Proceeds
Wednesday, 6 Mar 2019 

March 6 (Reuters) - Infinity Pharmaceuticals Inc ::INFINITY PHARMACEUTICALS ANNOUNCES ROYALTY MONETIZATION OF COPIKTRA FOR $30 MILLION GROSS PROCEEDS.INFINITY PHARMACEUTICALS INC - ANNOUNCED ROYALTY MONETIZATION WITH HEALTHCARE ROYALTY PARTNERS (HCR) FOR RIGHT TO RECEIVE CERTAIN ROYALTY PAYMENTS.INFINITY PHARMACEUTICALS INC - ROYALTY PAYMENTS BASED ON WORLDWIDE ANNUAL NET SALES OF COPIKTRA (DUVELISIB), PAYABLE BY VERASTEM.INFINITY PHARMACEUTICALS - UNDER AGREEMENT, HCR HAS AGREED TO PAY CO A $30 MILLION UPFRONT PAYMENT AND UP TO $20 MILLION IN POTENTIAL MILESTONE PAYMENTS.INFINITY PHARMACEUTICALS INC - IN CONNECTION WITH ROYALTY MONETIZATION, INFINITY ENTERED INTO AN AMENDMENT OF ITS LICENSE AGREEMENT WITH TAKEDA.INFINITY PHARMACEUTICALS - AS PER AMENDMENT OF LICENSE AGREEMENT WITH TAKEDA, TAKEDA HAS AGREED TO RECEIVE A PORTION OF TOTAL INVESTMENT AMOUNT.  Full Article

Photo

Japan's Astellas to buy Audentes for $3 billion in high-priced gene therapy bet

TOKYO Japan's Astellas Pharma Inc is buying U.S. drugmaker Audentes Therapeutics Inc for about $3 billion in cash, in a high-priced push to make genetic medicines a key area of growth.